
Opinion|Videos|December 7, 2023
EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC
Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS
Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.
Episodes in this series






































